Published in Postgrad Med on August 01, 1970
Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA (2001) 13.65
Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials (1997) 5.67
Recruitment experience in clinical trials: literature summary and annotated bibliography. Control Clin Trials (1987) 3.39
Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 2.96
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1994) 2.84
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation (2000) 2.07
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med (1981) 1.89
Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation (2001) 1.46
Factors influencing the development of hypercholesterolemia after cardiac transplantation. Am J Cardiol (1992) 1.39
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol (2000) 1.27
Increased leucocyte oxidative metabolism in hyperlipoproteinaemia. Lancet (1982) 1.20
Effects of a vigorous walking program on body composition, and carbohydrate and lipid metabolism of obese young men. Am J Clin Nutr (1979) 1.13
Long-term effects of clofibrate (Atromid-S) on serum lipids in man. Circulation (1969) 1.11
Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med (1994) 1.10
Cholesterol-lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia. Am J Clin Nutr (1990) 1.09
The Minnesota Regional Peripheral Arterial Disease Screening Program: toward a definition of community standards of care. Vasc Med (2001) 1.09
Lipids and hypertension. Implications of new guidelines for cholesterol management in the treatment of hypertension. Am J Med (1986) 1.08
Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology (1988) 1.04
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol (1998) 1.04
Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med (2001) 1.03
Relief of pain of Fabry's disease by diphenylhydantoin. Neurology (1973) 1.02
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol (1996) 1.00
Prescription writing by generic name and drug cost. J Chronic Dis (1967) 0.96
Drug interactions with warfarin. Arch Intern Med (1968) 0.95
Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results. Control Clin Trials (1987) 0.94
Diflunisal: a review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans. Br J Clin Pharmacol (1977) 0.93
Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes (1999) 0.92
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med (1987) 0.92
Patient perceptions about the influence of cholesterol on heart disease. Am J Prev Med (1992) 0.91
Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc (1997) 0.91
Treatment of type III hyperlipoproteinemia with four different treatment regimens. Atherosclerosis (1984) 0.90
Blood lipids and lipoproteins in a Minnesota urban population. J Chronic Dis (1980) 0.90
Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. J Nutr (1997) 0.89
Sensitivity of the canine pancreatic intraductal pressure to subclinical reduction in cholinesterase acitivity. Ann Surg (1979) 0.89
Interaction between diflunisal and warfarin. Clin Pharmacol Ther (1980) 0.88
Effect of cholestyramine and colestipol on the absorption of phenytoin. Eur J Clin Pharmacol (1983) 0.87
The effect of butoxamine on catecholamine-induced metabolic changes in humans. Clin Pharmacol Ther (1966) 0.87
Clofibrate effect on catecholamine-induced metabolic changes in humans. Metabolism (1968) 0.86
The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake. J Am Diet Assoc (1994) 0.85
Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis (1991) 0.84
Uricosuric properties of diflunisal in man. Br J Clin Pharmacol (1979) 0.84
Physiological markers of smoking and their relation to coronary heart disease. The Lipid Research Clinics Coronary Primary Prevention Trial. Arteriosclerosis (1987) 0.84
Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos (1994) 0.83
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Preferences and opinions of consumers vs dietitians on cholesterol education materials. J Am Diet Assoc (1991) 0.82
Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis (1992) 0.82
Human pharmacokinetics of two crystalline and galenic forms of diflunisal, a new analgesic. Pharm Acta Helv (1978) 0.81
Effects of cholestyramine and colestipol on the plasma concentrations of propranolol. Br J Clin Pharmacol (1984) 0.81
Safety of long-term large doses of aspartame. Arch Intern Med (1989) 0.81
Pharmacokinetics of propylthiouracil in man after a single oral dose. J Clin Endocrinol Metab (1975) 0.81
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin (2001) 0.81
The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol (1982) 0.81
Population characteristics according to recruitment source. Circulation (1982) 0.81
Intestinal HMG-CoA reductase activity is low in hypercholesterolemic patients and is further decreased with lovastatin therapy. J Lipid Res (1988) 0.81
Hyperlipidemia in long-term survivors of pediatric renal transplantation. Clin Transplant (1994) 0.80
Plasma cholesterol: an influencing factor in red blood cell oxygen release and cellular oxygen availability. J Am Coll Surg (2000) 0.80
Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis (1994) 0.80
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol (1998) 0.80
Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther (1989) 0.80
Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am J Cardiol (1997) 0.80
Blood lipid effects of antihypertensive therapy: a double-blind comparison of the effects of methyldopa and propranolol. J Clin Pharmacol (1984) 0.80
Gastrointestinal blood loss after diflunisal and after aspirin: effect of ethanol. Clin Pharmacol Ther (1978) 0.79
Cimetidine blockade of histamine-induced insulin secretion. Clin Pharmacol Ther (1980) 0.79
The chemistry, pharmacology and clinical pharmacology of diflunisal. Curr Med Res Opin (1978) 0.78
A double-blind comparison of a novel indanone diuretic (MK-196) with hydrochlorothiazide in the treatment of essential hypertension. Br J Clin Pharmacol (1979) 0.78
Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications. The Lipid Research Clinics Program Prevalence Study. Circulation (1980) 0.78
Recruitment from clinical studies. Circulation (1982) 0.78
Pharmacologic therapy for the hyperlipidemic patient. Am J Med (1983) 0.78
Evaluation of succinimidoethyl and pivaloyloxyethyl esters as progenitors of methyldopa in man, rhesus monkey, dog, and rat. Drug Metab Dispos (1979) 0.78
Effect of methylphenidate on plasma anticonvulsant levels. Clin Pharmacol Ther (1972) 0.78
Effect of human apolipoprotein E isoforms on plasma lipids, lipoproteins and apolipoproteins in apolipoprotein E-deficient mice. Atherosclerosis (1998) 0.77
Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Metabolism (1981) 0.77
Pneumocystis carinii pneumonia diagnosed from sputum and successfully treated with pentamidine isethionate. Cancer (1970) 0.77
Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med (1992) 0.77
Ascorbic acid supplement use and the prevalence of gallbladder disease. Heart & Estrogen-Progestin Replacement Study (HERS) Research Group. J Clin Epidemiol (1998) 0.77
Controlled trial of acifran in type II hyperlipoproteinemia. Clin Pharmacol Ther (1985) 0.77
Evaluation of implementation of a cholesterol management program in physicians' offices. Health Educ Res (1992) 0.77
Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia. Metabolism (1981) 0.76
Effects of lovastatin and warfarin on early carotid atherosclerosis: sex-specific analyses. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation (1999) 0.76
Appropriate days for measuring intake of dietary fat and cholesterol. Ann Nutr Metab (1992) 0.76
Histamine receptors in adipose tissue: involvement of cyclic adenosine monophosphate and the H2-receptor in the lipolytic response to histamine in isolated canine fat cells. J Pharmacol Exp Ther (1975) 0.76
Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia. Am J Med (1984) 0.76
Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin. Am J Cardiol (1993) 0.76
Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician. Arch Intern Med (1994) 0.76
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J (2000) 0.75
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol (2001) 0.75
Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans. Clin Ther (1984) 0.75
Effect of cimetidine on plasma lipids and lipoproteins. Clin Pharmacol Ther (1984) 0.75
Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia. Metabolism (1985) 0.75
Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate. Metabolism (1983) 0.75
Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide. Clin Pharmacol Ther (1986) 0.75
Carotenoids and vitamin A: the effect of hypocholesterolemic agents on serum levels. Metabolism (1985) 0.75
Effect of time of administration of cholestyramine on plasma lipids and lipoproteins. Artery (1985) 0.75
A screening survey of dyslipoproteinemias associated with prescription drug use. The Lipid Research Clinics Program Prevalence Study. Circulation (1986) 0.75